Dare Bioscience Inc
$ 1.72
3.61%
25 Feb - close price
- Market Cap 22,376,000 USD
- Current Price $ 1.72
- High / Low $ 1.73 / 1.65
- Stock P/E N/A
- Book Value 0.20
- EPS -1.83
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -25.43 %
- 52 Week High 3.28
- 52 Week Low 1.61
About
Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$10.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-05 | 2025-03-26 | 2024-11-07 | 2024-08-08 | 2024-05-14 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.28 | -0.45 | -0.5 | -0.65 | -0.55 | -0.88 | -0.07 | -0.06 | -0.09 | -0.1 | -0.09 | -0.19 |
| Estimated EPS | 0.02 | 0.03 | -0.58 | -0.6333 | -0.73 | 0.02 | -0.06 | -0.1 | -0.1 | -0.1 | -0.1 | -0.14 |
| Surprise | -0.3 | -0.48 | 0.08 | -0.0167 | 0.18 | -0.9 | -0.01 | 0.04 | 0.01 | 0 | 0.01 | -0.05 |
| Surprise Percentage | -1500% | -1600% | 13.7931% | -2.637% | 24.6575% | -4500% | -16.6667% | 40% | 10% | 0% | 10% | -35.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DARE
2026-02-24 14:52:27
Daré Bioscience Inc. has received FDA clearance for its Investigational New Drug application for DARE-HPV, allowing it to begin a Phase 2 clinical study for a non-surgical treatment for persistent high-risk human papillomavirus infection. The company's stock has seen a significant decline, but it holds more cash than debt and is supported by a $10 million contract. This development offers a potential non-surgical alternative to current HPV management, which primarily involves monitoring and surgical procedures for precancerous lesions.
2026-02-23 13:55:13
Daré Bioscience Inc. (NASDAQ:DARE) has received FDA clearance for its Investigational New Drug application for DARE-HPV, allowing it to proceed with a Phase 2 clinical study for the treatment of persistent high-risk human papillomavirus infection. DARE-HPV is a novel non-surgical, self-administered vaginal insert, addressing a significant unmet medical need as there are currently no approved pharmacologic treatments for HPV infection. The company plans to initiate the study in 2026, supported by a $10 million contract from the Advanced Research Projects Agency for Health.
2026-02-23 13:01:36
Daré Bioscience (NASDAQ: DARE) announced FDA clearance of its Investigational New Drug (IND) application for DARE-HPV, a topical vaginal insert designed to treat persistent high-risk HPV infection, the primary cause of cervical cancer. This clearance allows the company to initiate a Phase 2 clinical study for DARE-HPV, which is supported by a $10 million ARPA-H contract. The treatment aims to address the significant unmet medical need for pharmacologic therapies for HPV, as current standard care often involves surgical interventions after precancerous lesions develop.
2026-02-23 12:55:13
Dare Bioscience has announced that the FDA has cleared its Investigational New Drug (IND) application for DARE-HPV, enabling a Phase 2 clinical study for this potential treatment for persistent high-risk HPV infection. DARE-HPV is a non-surgical, localized therapy designed to clear the HPV virus, which is responsible for 99% of cervical cancer cases and currently has no FDA-approved pharmacologic treatments. The program is supported by a $10 million contract from ARPA-H, aiming to redefine cervical disease prevention by targeting the virus before precancerous lesions develop.
2026-02-23 08:00:00
Daré Bioscience has received FDA clearance for its Investigational New Drug (IND) application for DARE-HPV, a vaginal insert treatment for persistent high-risk HPV infection. This allows the company to proceed with a Phase 2 clinical study. DARE-HPV aims to be the first non-surgical, localized, self-administered therapy to target the HPV virus directly, potentially redefining cervical cancer prevention.
2026-02-13 10:58:02
Dare Bioscience has launched telehealth consultations for its DARE to PLAY Sildenafil Cream, a topical arousal cream designed for women to enhance genital blood flow and arousal. This initiative provides women nationwide with convenient access to a prescription for this clinically studied product through the DARE Health Hub. The company aims to address unmet needs in women's sexual health by offering a science-backed solution for female sexual arousal.
